---
document_datetime: 2023-09-21 19:10:51
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/viracept-epar-procedural-steps-taken-authorisation_en.pdf
document_name: viracept-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3836742
conversion_datetime: 2025-12-15 06:48:14.051145
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  company  Agouron  Pharmaceuticals  (Europe)  Ltd.,  submitted  on  13  February  1997  to  the European Agency for the Evaluation of Medicinal Products (EMEA) an application for the marketing authorisation of the medicinal product Viracept (nelfinavir) falling within the scope of Part B of the Annex of the Council Regulation (EEC) 2309/93, of 22 July 1993.

•

Medicinal product no longer authorised The Rapporteur and Co-Rapporteur appointed by the CPMP were: Rapporteur: Dr. D Jefferys Co-Rapporteur: Prof J.A.G. Morais Licensing status: Viracept  has  been  granted  a  license  in  several  non-EU  countries  including  USA,  where  it  was approved  for  adult  and  paediatric  use  in  March  1997.  In  Switzerland  it  was  approved  for  adult administration in June 1997 and for paediatric administration in April 1999. 2. Steps taken for the assessment of the product · A request for the inspection of the finished product-manufacturing site in the USA was agreed during  the  March  1997  CPMP  meeting  and  the  United  Kingdom  Inspectorate  performed  the inspection. · The  assessment  report  of  the  Co-Rapporteur  was  circulated  to  all  members  of  the  CPMP  on 10 April 1997. · The  assessment  report  of  the  Rapporteur  was  circulated  to  all  members  of  the  CPMP  on 11 April 1997. · During the May 1997 CPMP meeting, a consolidated list of questions was agreed upon which was sent to the applicant on 14 May 1997. · The applicant submitted the responses to the consolidated list of questions on 6 June 1997. · The joint  Rapporteur/Co-Rapporteur  assessment  of  the  responses  was  circulated  to  all  CPMP members on 17 July 1997. · The applicant provided supplementary information on 10 September 1997. · In agreement with Agouron Pharmaceuticals (Europe) Limited on the 19 September 1997 Roche Registration Limited duly replaced Agouron Pharmaceuticals (Europe) Limited as the applicant for the above-mentioned marketing authorisation. · The future marketing authorisation holder signed a letter of undertaking on follow-up measures on 24 September 1997. · The CPMP on the basis of the favorable benefit-risk assessment issued a positive opinion for granting  a  marketing  authorisation  in  exceptional  circumstances  to  Viracept  on  24  September 1997. The CPMP opinions were forwarded, in all official  languages  of  the  European  Union,  to the European Commission, which adopted the corresponding Decision on 22 January 1998 .